Board of Directors

Scott Huennekens
Chairman of the Board
Scott Huennekens has more than 25 years of experience in the medical device industry, specializing in clinical advancement through innovative R&D and technology-based initiatives. He has held a number of executive leadership roles within the healthcare industry, accelerating the next generation of digital surgery for Verb Surgical and leading Volcano Corporation, an image guided therapy device company, to its IPO in 2006. He holds an MBA from Harvard University and a BS in Business Administration from the University of Southern California. Huennekens currently sits on the boards of public companies Envista and NuVasive.
Chairman of the Board
Daniella Cramp
Director
Ms. Cramp has over 25 years of experience in the medical device and pharmaceutical industries, with particular expertise in the cardiovascular industry. Since 2019, she has been with Thermo Fisher Scientific, a scientific instruments equipment and supplies company with annual revenue exceeding $25 billion, currently serving as Senior Vice President and President, BioProduction Group. Prior to her role with Thermo Fisher Scientific, Ms. Cramp served as Global President for Johnson & Johnson’s (J&J’s) neurovascular medical device business and as U.S. President for Biosense Webster, J&J’s electrophysiology business. Before Biosense Webster, Ms. Cramp held various roles with Alere, Inc., a global manufacturer of rapid point-of-care diagnostic tests, culminating in her role as Global President of the Cardiometabolic Business unit.
Jim Hinrichs
Lead Independent Director
Jim Hinrichs has served as a member of our board of directors and chair of our Audit Committee since October 2019. Hinrichs has over 25 years of corporate finance experience and previously served as Executive Vice President and Chief Financial Officer of Alere, Inc., a publicly traded, global diagnostics company, from April 2015 until its sale to Abbott Labs for approximately $8 billion in October 2017. Prior to joining Alere, Inc., Hinrichs served as Chief Financial Officer of CareFusion Corp., a publicly traded medical device company, from December 2010 until its sale to Becton Dickenson for $12 billion in March of 2015. Before that, Hinrichs held various financial leadership positions at CareFusion, Cardinal Health and Merck & Co. He is a member of the Board of Directors, and Audit Committee Chair, of Orthofix and a Member of the Board of Directors, and Compensation Committee Chair, of Integer Holdings. He holds graduate and undergraduate degrees in business from Carnegie-Mellon University.
Dr. Andrew ElBardissi
Director
Dr. Andrew ElBardissi is an investor on the Private Transaction team at Deerfield Management. Prior to joining Deerfield, Dr. ElBardissi held roles as an early stage life-sciences investor at Longitude Capital and as an Investment Banker at J.P. Morgan’s Healthcare practice. Dr. ElBardissi holds an MD from Mayo Clinic, an MPH in Quantitative Methods from Harvard University, and an MBA from Harvard Business School. He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ), has over 30 publications in leading peer reviewed scientific journals, and has presented his research at numerous medical and surgical conferences.
Dr. David Bonita
Director
Dr. David Bonita is a Private Equity Partner at OrbiMed, where he serves on the boards of Loxo Oncology, Kyn Therapeutics, Clementia Pharmaceuticals, Tricida, Prelude Therapeutics, ViewRay, SI Bone and Keystone Heart. He previously served on the boards of Enobia Pharma, CardiAQ and Ambit Bioscience. Prior to joining OrbiMed, Dr. Bonita worked in the healthcare investment banking groups of Morgan Stanley and UBS. He has published several scientific articles in peer-reviewed journals based on research performed at the Harvard Medical School. Dr. Bonita received his AB degree magna cum laude in Biological Sciences from Harvard University and his joint MD/MBA from Columbia University where he was elected to the Alpha Omega Alpha Medical Honor Society and Beta Gamma Sigma Business Honor Society.
Dr. Shaden Marzouk
Director
Dr. Marzouk is currently CEO, Health, for Hudson's Bay Company, a position she has held since July 2021. Previously, Dr. Marzouk was President of CareMore Health and Aspire Health, subsidiaries of Anthem, Inc., a position she held from March 2020 to July 2021. From September 2018 to February 2020, Dr. Marzouk was Managing Director, Health and Global Health Innovation, of AXA S.A.’s health insurance and health services business in Asia. Prior to AXA, Dr. Marzouk served as Cardinal Health, Inc.’s Medical Segment Chief Medical Officer from November 2016 to August 2018, its Senior Vice President, Clinical Operations from April 2015 to August 2016, and its Vice President, Clinical Operations from February 2012 to April 2015. Prior to AXA, Dr. Marzouk was an investment banking associate in Goldman Sachs & Co. LLC’s Healthcare Group in 2010 and 2011. Dr. Marzouk also served in the U.S. Army on active duty from July 2006 to July 2009, where she practiced as a neurosurgeon and served in Iraq as a Major. Dr. Marzouk received an MBA from The Fuqua School of Business, Duke University, an MD from St. Louis University School of Medicine, and a BA from the Washington University in St. Louis. Dr. Marzouk also advises health technology companies and serves on the advisory boards in the healthcare industry.
Niamh Pellegrini
Director
Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. Ms. Pellegrini has previously served as Vice President of Global Commercial Operations for Abbott Vascular, where she was responsible for driving approximately $3 billion in revenue, and as CEO and President at Autonomic Technologies, Inc., leading a turnaround of its European commercial business and driving U.S. market access. Ms. Pellegrini has also held positions in leadership, global business development, strategy and commercial with Thoratec Corporation and Johnson & Johnson. She earned both a B.S. and an M.B.A. from Santa Clara University.
John Sheridan
Director
Since March 2019, John Sheridan has been the President and Chief Executive Officer of Tandem Diabetes Care, Inc., a medical device company specializing in the design, development and commercialization of products for people with insulin-dependent diabetes. He has been a member of Tandem’s Board of Directors since June 2019 and a member of the executive management team since 2013. Prior to joining Tandem Diabetes Care, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation, a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.